Be Active. Heal Better. Live Fully.

Reg CF Equity Offering

$1.23M target raise • $62 million pre-money valuation

Precision Medicine Meets Precision Innovation. We combine surgeon-defined R&D with same-week, in-house manufacturing to deliver implants that reduce risk, increase efficiency, and cost less.

6,000+

Implants Helping Patients

75%

Gross Margin

Patents Filed

$9.00

Share Price

$999

Minimum Investment

Invest Now

SEC Filings Offering Circular Investor Education

40+ Elite Surgeons

FDA Cleared

$12B Market

Investment Tiers & Rewards

Choose your investment level and unlock exclusive bonus shares. Each tier is designed to reward larger commitments with increased ownership and exclusive investor benefits.

Zero Investor Fees

Unlike most crowdfunding investment opportunities that charge investors 3%+ in fees, Aevumed absorbs all platform costs. This means you get more equity for your investment—every dollar goes directly toward your ownership stake.

Member

$1,000

Standard Shares

Silver

$5,000

+5% Bonus Shares

Gold

$10,000

+8% Bonus Shares

Platinum

$15,000

+10% Bonus Shares

Diamond

$25,000

+12% Bonus Shares

VIP

$40,000

+15% Bonus Shares

Ready to Invest in Innovation?

Choose your investment tier and join the revolution in orthopedic care. Every investment includes the potential for substantial returns as we scale our breakthrough technologies.

Start Investing

Precision Medicine Meets Precision Innovation

The Silent Epidemic

Orthopedic soft-tissue failure is a silent epidemic. Rotator-cuff tears alone require over 460,000 surgeries per year¹, and for large tears more than half of "repaired" tendons rip again. Behind every statistic is a person who can't lift a coffee mug, hug a child, or return to sport without pain.

Breaking the Cycle

Aevumed exists to break that cycle.

We combine surgeon-defined R&D with same-week, in-house manufacturing to deliver implants designed to reduce risk, apply surgical efficiency, install faster, and cost less than the status-quo alternatives.

Our mission is simple and measurable: restore functionality so people everywhere can be active, heal better, and live fully.

The Innovation Bottleneck We Eliminated

The Old Way

Traditional device giants chase spectacle—splashy robots and generic "AI dashboards." They outsource prototypes, wait a quarter for feedback, then launch at a price hospitals can't absorb. Surgeons are left improvising, and patients absorb the risk.

Aevumed flips the model.

Clinical-First Feedback

Forty elite sports-medicine surgeons meet with our engineers every month. Their pain points—not marketing trends—define the roadmap.

Rapid Iteration

Smart CNC, robotic additive printing, and a custom 3D bioprinter cut prototype time from twelve weeks to one and cost from $10,000 to < $100.

Economic Discipline

From first sketch we design to land below the ASC reimbursement cap, ending the budget tug-of-war that slows adoption.

Defensible IP

Seventeen patents filed, nine trademarks processed, and about three new provisionals drafted each year secure every core technology.

The Result

The result is an 18-product pipeline stretching from shoulder to hip, knee, foot, ankle, and hand — each born from the same agile, surgeon-driven loop.

Our Flagship Products

PHANTOM-LP Knotless Anchor

First anchor surgeons can lock, unlock, and re-tension in under 60 seconds. the only knotless suture anchor on the market that enables surgeons to adjust suture tension after the anchor has been seated into bone. Competing products do not offer this level of intraoperative control—once their anchors are deployed, the position and tension of the sutures are fixed. As a result, if a suture is too loose or not optimally positioned over the tendon, the surgeon must leave the repair as-is, with no option for refinement.
Patented Bone-Shield™ spreads force "like a spoon on cheese," preventing bone erosion. The only knotless anchor that fully houses all sutures within the body of the anchor, rather than leaving them exposed outside. This innovation significantly reduces the risk of suture abrasion and bone cut-through—an issue common in other designs—which can compromise pullout strength, lead to anchor or suture loosening, and ultimately jeopardize the integrity of the tendon repair.
2,000 human implanted. delivers exceptional mechanical performance, offering pullout strength significantly higher than any other push-in anchor on the market, and comparable to leading screw-in anchors. This makes it a uniquely robust and versatile option for surgeons seeking precision, safety, speed, and reliability in tendon repair procedures.
Self-punching, one-piece design that eliminates the need for a separate pilot hole or awl. Unlike other self-punching anchors—which are often two-piece systems or contain metal components—PHANTOM-LP is made from 100% PEEK and is metal-free, minimizing the risk of breakage during insertion and improving overall biocompatibility.

What is PEEK?

PEEK stands for Polyether Ether Ketone, a high-performance thermoplastic polymer known for its excellent mechanical and chemical resistance properties, particularly at high temperatures. It's a semi-crystalline material, meaning it's opaque and can withstand high temperatures and chemical environments. Critically, PEEK has similar elasticity to bone, making it biomechanically compatible for orthopedic applications.

PHANTOM-X 3D Bioprinted Scaffold

Only scaffold designed to reinforce both superior and inferior tendon surfaces fabricated using Aevumed's propriety 3D printing technology, BioTendon 3D™
+60% repair strength in bench testing; installs in three minutes through standard portals
Anchor-plus-scaffold kit lands under the reimbursement ceiling—no surprise bills, no admin fights
All-in-one scaffold, suture, and suture passer delivery system that requires low training for surgeons while providing ease of use and simplicity

PHANTOM

MicroThread technology for superior pullout strength
Vented holes for bone ingrowth
Multiple configurations

PHANTOM-3.5/4.5

Self-punching
Small profile
Superior pullout strength

PHANTOM-NANO

Controllable cinching mechanism
Self-punching
Superior pullout

RAPID

Percutaneous insertion
Knotted and knotless options
Quick and easy insertion

SUPERCYNCH

Mechanical flipping mechanism
Unidirectional tensioning
Small profile

PROTEKT

Quick and easy insertion
Improved bone and tendon contact
No tendon wrapping

HIP LABRUM

Superior pullout
Small profile
Self-cinching

FASE

Boneshield technology
Multi-lock suture Re-Tension Technology
Reduced footprint

Execution to Date

Proven results demonstrate our ability to deliver innovation that matters—from 6,000 patients helped to strong financial performance and a robust IP portfolio.

6,000+

Implants Helping Patients

Real patients, real results, real impact on lives today

75%

Gross Margin

On in-house production, trending toward 80%

Patents Filed

Nine trademarks processed securing core technology

Camera Patent Pending

Future real-time guidance in the OR

Products by 2027

Ten commercial products by 2026

Market Opportunity

Massive Market

$12B

Sports Medicine Devices

8.23%

Annual Growth Rate

Sports Medicine is the fastest growing sector in Orthopedics. Sports-medicine devices total $6.4B to $12.04B (2025-2033) with 8.23% CAGR². Arthroscopy devices reach $7.26B - $14.8B (2025-2032)³, with the broader orthopedic market at $64B⁴.

Exit Potential

Exit Target +$400M

Multi-Product Platform Value

Aevumed is intentionally multi-product, producing disruptive technologies in all sports medicine, positioning us for a premium outcome and/or a self-sustaining revenue engine—whichever path creates greater shareholder value.

References:

¹ iData Research. Over 460,000 Rotator Cuff Surgeries Per Year Reported in the United States

² Precedence Research. Sports Medicine Market Size to Hit USD 13.03 Billion by 2034

³ Data Bridge Market Research. Global Arthroscopy Devices Market

⁴ OrthoWorld. Orthopedic Market Size and Share

⁵ Historical orthopedic company exit multiples and valuations (Click for details)

Financial Highlights*

Proven Growth Trajectory

139%

Revenue Growth
2022-2024

$5M*

Forecast 2026
Revenue Target

Revenue Growth Trajectory

Revenue grew from $287k (2022) to $684k (2024) from only one to two products with no external marketing budget.

Strategic Milestones

Forecast $5 million in 2026* and cash-flow breakeven immediately after PHANTOM-X clearance (targeted Q4 2026).

* Assuming Reg CF Round Closes in December 2025

⚠️ Important Forward-Looking Statements Disclaimer

Forward-Looking Statements: This section contains forward-looking statements regarding revenue projections, cash flow expectations, and product launch timelines. These statements are based on current expectations and assumptions and involve substantial risks and uncertainties.

Key Underlying Assumptions:

Successful FDA clearance of PHANTOM-X by Q4 2026
Continued surgeon adoption and product demand growth
Ability to scale manufacturing capacity as planned
No significant changes in healthcare reimbursement policies
Successful completion of this funding round
Retention of key personnel and surgeon advisors

Key Risk Factors:

Regulatory delays or rejection of product clearances
Competitive pressures from established medical device companies
Changes in healthcare policies or reimbursement rates
Manufacturing scaling challenges or supply chain disruptions
Clinical adoption rates may be slower than anticipated
Need for additional capital beyond current projections

*Actual results may differ materially from these projections. Please review the complete risk factors and audited financial statements in the Form C before making any investment decision.

Investment Thesis

Why Any Investor Can Win with Aevumed

Four pillars of sustainable competitive advantage

Proven innovation engine that is unique and can't be easily replicated

Surgeon-led adoption that accelerates revenue without payer friction

High-margin, capital-efficient manufacturing that funds its own growth

Mission-driven brand positioned for significant strategic interest

What Makes Aevumed Unique?

Clinical-First DNA

Every product begins with problem definitions from our network of forty practicing surgeons—not from market surveys or trend decks. That front-line insight ensures we address real intra-operative pain points and deliver tangible improvements in healing.

One-Week Prototype Cycle

In-house Swiss CNC, robotic additive printers, and a custom 3D bioprinter reduce prototype time from twelve weeks to about one week, slashing costs from $10,000 to under $100. Rapid iteration means faster regulatory filings, quicker surgeon feedback, and a shorter path to revenue.

Reimbursement-Ready Pricing

Because manufacturing costs are engineered down from day one, every kit launches at or below the ASC reimbursement ceiling. Surgeons adopt without fighting hospital finance committees, and patients avoid out-of-pocket surprises.

Seventeen Patents—and Growing

A disciplined IP strategy protects anchors, scaffolds, instrumentation, and forthcoming AI guidance. Roughly three new provisional filings each year secure fresh white space while locking out copy-cat designs.

Multi-Product, Multi-Joint Pipeline

Most ortho start-ups live or die on a single device. Aevumed already has ten commercial products under development with some already on the market and eighteen launches slated by 2027, spanning shoulder, hip, knee, foot, ankle, and hand. A diverse pipeline de-risks the business and expands total addressable market beyond $16 billion.

Surgeon Advisory Alignment

Advisory surgeons vote on R&D priorities and participate in cadaver labs. Their passion for innovation that has not been fulfilled by the rest of the industry is tied to clinical success, creating a feedback loop traditional OEMs can't match.

Revenue & Capital-Efficient Economics

Aevumed is revenue generating with products being used at the top medical institutions in the US. With 75% gross margin today—and a trajectory toward 80%—Aevumed funds a meaningful share of R&D from operating cash, limiting dilution and making investor capital work harder.

Stellar Management Team

Collectively, Aevumed has an impressive management team, advisors, and board with over 200 years of experience in the medical device orthopedic space. The founders of Aevumed are deeply committed to the company's vision and lead with a hands-on, purpose-driven approach. They have fostered a bold culture rooted in the principle of "no remorse" — a mindset that challenges the orthopedic industry's outdated, 20th-century approach to innovation. By pursuing unconventional paths and pushing the boundaries of what's possible, Aevumed is developing truly advanced technologies that deliver meaningful value to surgeons, elevate the healthcare system, and, most importantly, improve patient outcomes. Be Active. Heal Better. Live Fully.

These factors combine into a competitive advantage that is neither easily acquired nor quickly copied—positioning Aevumed to change the standard of care while delivering outsized value to its shareholders.

Use of Proceeds

Strategic allocation of investment capital to accelerate growth, expand production capabilities, and advance our innovative product pipeline

Scale Production

Scale production of cleared products and purchase additional additive manufacturing lines to meet growing demand

Sales & Marketing

Sales and marketing on all fronts to achieve financial goals and expand market penetration across key therapeutic areas

R&D Pipeline

R&D of multiple products in Aevumed's pipeline to maintain our innovation advantage and expand our product portfolio

510(k) Submissions

Complete 510(k) submissions for PROTEKT, PHANTOM-X, FASE, and NANO to bring breakthrough technologies to market

Clinical Studies

Expand clinical-outcome studies and surgeon education programs to demonstrate superior patient outcomes

AI Camera Program

Advance AI-camera program toward future FDA filing for real-time surgical guidance and improved patient outcomes

Strategic Capital Allocation

Production & Manufacturing

35%

Sales & Marketing

25%

R&D & Pipeline Development

20%

Regulatory & Clinical Studies

15%

AI Innovation & Technology

Target Investment Impact

Revenue Target 2026: $5M

Cash Flow Breakeven: Q4 2026

Products by 2026: 10

Total Pipeline by 2027: 18

This strategic allocation ensures rapid growth while maintaining our commitment to innovation and clinical excellence. Your investment directly accelerates the development of breakthrough medical technologies that will help millions of patients.

Invest in Innovation

Leadership You Can Trust

Stellar management team with over 200 years of combined experience in the medical device orthopedic space

200+

Years Combined Experience

40+

Elite Surgeon Advisors

$500M+

Revenue Experience

Former AAOS Presidents

Executive Leadership

20+ years R&D and commercialization

Saif Khalil, PhD

Founder, Chairman & CEO

Former VP Neuromodulation at Globus Medical (GMED), reporting directly to CEO. MS Materials Science, PhD Mechanical Engineering from Drexel University.

"When surgeons define the problem, it leads to solutions that actually matter—it's our foundation. Aevumed is solving the problems legacy companies still haven't figured out." — Saif Khalil, PhD

10+ years medical device development

Miles Curtis

VP R&D

Former Globus Medical engineer specializing in Class II and III implantable devices. Extensive surgeon collaboration in cadaver labs. BS Mechanical Engineering from RPI, Six Sigma Green Belt.

"Working directly with surgeons in the field transforms theoretical designs into devices that actually work. Every prototype we build is tested in real surgical environments." — Miles Curtis

35+ years healthcare leadership

William Warrender, Jr.

SVP Sales

Strategic Medical Device Executive with global experience. Former leadership at Cardinal Health, Cleveland Clinic, Smith & Nephew, Medartis, DJO, Zimmer, J&J. MBA from Notre Dame.

"The best medical device companies don't just sell products—they build partnerships with surgeons that transform patient outcomes. That's the Aevumed difference." — William Warrender, Jr.

Board of Directors

David Farmer

Board Member

Former CFO of Smith & Nephew Trauma Global. Former President of Optum (acquired by strategic). BBA Accounting & Marketing, MBA University of Memphis.

Bill Shopoff

Board Member

40+ years Sales & Marketing. Former Global President of Smith & Nephew Trauma & Extremities ($500M+ annually). Former EVP Global Sales at Exactech.

Gerald Williams, Jr., MD

Board Member

Former President of American Academy of Orthopaedic Surgeons (AAOS) and American Shoulder and Elbow Surgeons (ASES). Professor at Sidney Kimmel Medical College.

Our Culture of "No Remorse"

The founders of Aevumed lead with a hands-on, purpose-driven approach, fostering a bold culture rooted in the principle of "no remorse" — a mindset that challenges the orthopedic industry's outdated, 20th-century approach to innovation. By pursuing unconventional paths and pushing the boundaries of what's possible, Aevumed is developing truly advanced technologies that deliver meaningful value to surgeons, elevate the healthcare system, and most importantly, improve patient outcomes.

Be Active. Heal Better. Live Fully.

Medical Advisory Board

Board-certified specialists who guide our clinical development and ensure our innovations meet real-world surgical needs

Christopher Dodson, MD

Board-Certified Sports Medicine Surgeon

Professor of Orthopaedic Surgery at Thomas Jefferson University. Currently serves as consultant to the National Hockey League (NHL) and Head Team Physician for Eastern University. Previously Associate Head Orthopedic Surgeon for the Philadelphia Eagles, Head Team Physician for the Philadelphia 76ers, and consultant for the Los Angeles Dodgers. Clinical interests include Shoulder Instability, ACL reconstruction, Rotator Cuff Tears, and Elbow Injuries in Overhead Athletes. Authored over 90 articles and book chapters, consistently recognized as "Top Doctor" in the region.

Peter Johnston, MD

Board-Certified Shoulder & Elbow Specialist

Board-certified specialist committed to compassionate, patient-centric care for shoulder and elbow problems. Manages complex problems with both open and arthroscopic methods including arthritis, rotator cuff tears, instability, and fractures. Member of American Shoulder Elbow Surgeons. BS Neurosciences from University of Michigan, medical training at Wayne State University with honors. Completed orthopaedic surgery training at University of North Carolina and fellowship at Rothman Institute, Thomas Jefferson University. Additional training in Lyon, France with world leaders in shoulder replacement.

Mark Lazarus, MD

Former Division Chief, Rothman Orthopaedic Institute

Fellowship trained, board certified shoulder and elbow surgeon. Former Division Chief of The Rothman Orthopaedic Institute Shoulder and Elbow Service and Professor of Orthopaedic Surgery at The Sidney Kimmel School of Medicine, Thomas Jefferson University. Lectures worldwide and has authored numerous articles on all aspects of shoulder and elbow surgery. Specializes in shoulder and elbow replacement and has helped design several shoulder prostheses. Pioneer in arthroscopic shoulder surgery, including rotator cuff repair and stabilization surgery. BA from Johns Hopkins University, MD from University of Medicine and Dentistry of New Jersey.

Surena Namdari, MD

Fellowship Director & Co-Director of Research

Board certified shoulder and elbow surgeon and Professor of orthopedic surgery at Thomas Jefferson University. Fellowship Director and Co-Director of Research for the Shoulder and Elbow Division. Medical school at Brown University, orthopedic residency at University of Pennsylvania, fellowship in Shoulder and Elbow Surgery at Washington University in St Louis. Specializes in arthroscopic and open treatment of all shoulder and elbow conditions, particularly complex problems involving bone loss, irreparable tendon tears, or failed previous surgery. Committed to evidence-based medicine with extensive bibliography and international presentations. Actively involved in medical device innovation and design.

Matthew Ramsey, MD

Board Certified Shoulder & Elbow Specialist

Board certified shoulder & elbow specialist with extensive publications and invitational lectures before the American Academy of Orthopaedic Surgeons and the International Congress on Surgery of the Shoulder, establishing him as a key physician among his medical peers. BA from State University of New York at Binghamton, MD from State University of New York Health Science Center at Brooklyn. Completed internship in General Surgery at Long Island Jewish Medical Center, residency in Orthopaedic Surgery at Thomas Jefferson University Hospital, and fellowship in Shoulder Surgery at University of Pennsylvania Medical Center.

Gerald Williams, Jr., MD

Former President of AAOS and ASES

Board certified shoulder specialist who served as President of the American Academy of Orthopaedic Surgeons (AAOS) and President of the American Shoulder and Elbow Surgeons (ASES). Professor of Orthopaedic Surgery at Sidney Kimmel Medical College and Director of the Shoulder and Elbow Center at Rothman Orthopaedic Institute. Has been instrumental in the development of many orthopedic implants and has collaborated with leading orthopedic companies. Medical degree from Temple University, Fellowship in Shoulder Reconstruction from University of Texas in San Antonio.

Surgeon Advisory Board

Elite surgeons who vote on R&D priorities and participate in cadaver labs, creating the clinical feedback loop that drives our innovation

Mark Frankle, MD

Pioneer of Reverse Shoulder Arthroplasty in the US

With Florida Orthopaedic Institute since 1991, fellowship training at Mayo Clinic. Board-certified by the American Board of Orthopaedic Surgery, specializing in shoulder and elbow surgery. Dr. Frankle brought reverse shoulder arthroplasty to the United States with revolutionary lateralized center of rotation design. His surgical outcomes remain an enduring testament to the viability of shoulder arthroplasty. The tenets of his implant design for reverse prostheses are now mirrored by every major orthopaedic implant manufacturer. Holds numerous patents on implants including anatomic total shoulder, reverse total shoulder prosthetics and suture removal systems. Worldwide acclaim as the preeminent expert on reverse shoulder arthroplasty.

Seth Gasser, MD

30-Year Sports Medicine Veteran

With Florida Orthopaedic Institute since 1993. University of Maryland School of Medicine graduate Magna Cum Laude, member of Alpha Omega Alpha Honor Society. Board-certified in Orthopaedic Surgery with subspecialty certification in Sports Medicine. Head team physician for University of Tampa and multiple preparatory schools. Previously served professional organizations including Tampa Bay Lightning, Tampa Bay Buccaneers, University of South Florida. 30-year member of AAOS and Arthroscopy Association of North America. Clinical Professor at University of Tampa, Vice President of Florida Orthopaedic Institute. Voted "Best Doctors in America" for 25 consecutive years.

Felix "Buddy" Savoie, MD

2022-23 President of AAOS

Internationally-recognized expert in Shoulder and Elbow Surgery and Sports Medicine. Professor of Clinical Orthopaedics at Tulane University School of Medicine, Chairman of Department of Orthopaedics, Ray J. Haddad Professor of Orthopaedics. 2022-23 President of the American Academy of Orthopaedic Surgeons (AAOS), 2016-17 President of the American Shoulder and Elbow Society, former President of the Arthroscopy Association of North America (AANA). Board-certified in Orthopaedic Surgery and Sports Medicine. Fellowship training at Medical College of Wisconsin, Mayo Clinic, A-O International Fellowship in Basel, Switzerland. Many patients travel nationally for his expertise with professional, college, and high school athletes.

Mark Drakos, MD

HSS Team Orthopedist NY Knicks/Mets

Orthopedic surgeon specializing in foot, ankle, and sports medicine at Hospital for Special Surgery. Team Orthopedist for the New York Knicks and New York Mets, consultant to professional sports teams including UFC. Medical Director for HSS Long Island and Fellowship Director for Foot and Ankle Service. Harvard University biomedical engineering graduate and four-year varsity football player. Board certified in orthopedic surgery with subspecialty certification in sports medicine. Author of over 100 peer-reviewed articles and recipient of multiple research grants. Fellowship training in sports medicine at HSS and foot/ankle surgery at Brown University.

40+ Elite Surgeon Network

Our complete network of 40+ elite sports-medicine surgeons meet with our engineers every month. Their pain points—not marketing trends—define our innovation roadmap.

Frequently Asked Questions

General Investment Questions

Why invest in startups?

Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on crowdfunding platforms; with Regulation CF Offerings, you aren't buying products or merchandise - you are buying a piece of a company and helping it grow. Aevumed represents an opportunity to invest in breakthrough orthopedic technology that addresses a massive medical need.

How much can I invest?

Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.

How do I calculate my net worth?

To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person's primary residence). The resulting sum is your net worth.

What are the tax implications of an equity crowdfunding investment?

We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.

Who can invest in a Regulation CF Offering?

Individuals over 18 years of age can invest.

What do I need to know about early-stage investing? Are these investments risky?

There will always be some risk involved when investing in a startup or small business. And the earlier you get involved typically means there is more risk present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That's why startups should only be part of a more balanced, overall investment portfolio.

When can I expect a return on my investment?

The Common Stock of Aevumed is not publicly traded, meaning the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: the company gets acquired by another company or the company goes public (makes an initial public offering). In these instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. If the value of our company grows, you have a higher potential of making a profit on your investment during one of these exits. However, sometimes there will not be any return due to business failure.

Can I sell my shares?

Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions. Exceptions to limitations on selling shares during the one-year lockup period: In the event of death, divorce, or similar circumstances, shares can be transferred to: i. The company that issued the securities ii. An accredited investor iii. A family member (child, stepchild, grandchild, parent, stepparent, grandparent, spouse or equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships)

What happens if a company does not reach their funding target?

If Aevumed does not reach its minimum funding target, all funds will be returned to the investors after the close of the offering.

How can I learn more about Aevumed's offering?

All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering, including our SEC filings and offering circular.

What if I change my mind about investing?

You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurs. If you've already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: [email protected]

How do I keep up with how Aevumed is doing?

At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.

What is DealMaker Securities?

DealMaker Securities ("DealMaker") is a Funding Portal registered with the SEC and a member of FINRA. Under Regulation Crowdfunding, DealMaker Securities acts as an intermediary platform for Issuers (companies selling securities in compliance with the regulations) and Investors (individuals purchasing securities offered by Issuers). DealMaker Securities does not provide investment advice or make any investment recommendations to any persons, ever.

What relationship does Aevumed have with DealMaker?

Once an offering ends, the company may continue its relationship with DealMaker for additional offerings in the future. DealMaker's affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.

About the Current Raise

What's your share price?

$9.00 per share.

What is the minimum investment amount?

The minimum investment amount is $999.

What kind of shares are you issuing?

We are issuing Common C shares.

How much are you raising?

We are currently raising $1.23M in this Regulation CF offering.

What is the current valuation of the company?

The Securities are priced arbitrarily and the Company makes no representations as to the reasonableness of any specified valuation.

Why should I invest in Aevumed?

Investing in Aevumed offers a unique opportunity to be part of a revolutionary orthopedic technology company addressing a massive unmet medical need. With over 460,000 rotator cuff surgeries performed annually, our precision medicine approach and breakthrough tissue repair technologies position us in a sports medicine devices market worth $6.4B to $12.04B (2025-2033). Led by an experienced team with deep medical device expertise, we're developing multiple disruptive technologies across all areas of sports medicine, positioning us for premium exit opportunities historically valued at $210-275M for single-product orthopedic companies.

How will Aevumed make money?

Aevumed will generate revenue through multiple streams including medical device sales to hospitals and surgical centers, licensing agreements with larger medical device companies, and potential royalty arrangements. Our products target the large and growing orthopedic surgery market, with particular focus on sports medicine procedures that represent a multi-billion dollar opportunity.

How do you plan to use the proceeds from this funding round?

The proceeds will be allocated to: Fees to Intermediary, Business Operations, Sales and Marketing, Repayment of debt, Inventory, Intellectual Property, and Capital Equipment.

When will I receive my shares?

Shares will be issued approximately 1-2 months after the fundraise closes.

About Aevumed

What is Aevumed's core business?

Aevumed is a precision medicine company focused on revolutionizing orthopedic soft-tissue repair. Our core business involves developing breakthrough technologies for treating rotator cuff tears and other orthopedic injuries that affect millions of Americans. We combine advanced biomaterials, surgical techniques, and precision medicine approaches to improve healing outcomes and reduce re-injury rates in sports medicine and orthopedic surgery.

Where are your headquarters?

109 Great Valley Parkway, Malvern, PA 19355

How many employees do you have?

Aevumed currently has 9 employees.

When will Aevumed expand into additional markets and revenue streams and which ones?

Aevumed is intentionally developing multiple products across all areas of sports medicine. Our expansion strategy focuses on building a comprehensive portfolio of disruptive technologies for orthopedic soft-tissue repair, including applications for hip, knee, foot, and hand indications. This multi-product approach positions us to capture a larger share of the $16+ billion total addressable market and creates multiple pathways for growth and potential exit opportunities.

What is the exit plan for Aevumed?

Aevumed is positioned for multiple potential exit strategies. Single-product orthopedic companies have historically achieved exits in the $210-275M range at double-digit revenue multiples. As an intentionally multi-product company developing disruptive technologies across all sports medicine applications, we are positioned for either a premium acquisition outcome or the development of a self-sustaining revenue engine - whichever path creates greater shareholder value. Potential acquirers include major medical device companies, pharmaceutical companies, and private equity firms focused on the healthcare sector.

What stage of development are Aevumed's products in?

Aevumed has products at different development stages: products on the market, products under FDA review, products going through verification and validation testing, and products in design stage.

Who are Aevumed's key competitors?

Our key competitors include Arthrex, Smith & Nephew, Zimmer Biomet, Stryker, J&J Medtech, and Conmed.

What intellectual property does Aevumed have?

Aevumed has 17 filed patents and 9 trademarks.

What regulatory approvals will Aevumed need?

We have 3 products with 510(k) clearance letters received from FDA, 3 products currently under FDA review, and 4 more products will need to be submitted to the FDA.

Who is on Aevumed's leadership team?

Saif Khalil, PhD - Founder, CEO, and Chairman
Miles Curtis - VP R&D
Bill Warrender - SVP Sales

What clinical data supports Aevumed's technology?

The company distinguishes itself by conducting R&D with a clinical-first approach, identifying specific patient needs before designing products, unlike the trend-focused strategies often seen in the medical device industry. This unique focus allows Aevumed to deliver minimally invasive implants and instruments that enhance healing, reduce recovery times, and improve long-term outcomes, especially in tendon, ligament, and bone integration. Leveraging advancements in 3D printing, biomaterials, and AI-driven analytics, Aevumed collaborates closely with orthopedic surgeons to meet unmet clinical needs in sports and regenerative medicine, positioning itself as a leader in patient-focused innovation.

What partnerships does Aevumed have?

None. All IP is developed by and assigned to Aevumed.

Important Disclosures

Forward-Looking Statements Disclaimer

The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements, which constitute forward looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

Crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Any past performance described is not indicative of future results. Historical experiences are not indicative of future results. Further, investors may receive illiquid and/or restricted securities that may be subject to holding period requirements and/or liquidity concerns. The securities described may be equities, debt, or hybrid securities or derivatives. Each of these also have specific risks and differences based on the characteristics, referred to as the terms of the securities. Please review the Investor Education/FAQs to learn more about these risks.

DealMaker Securities LLC, a registered broker-dealer, and member of FINRA | SIPC, located at 4000 Eagle Point Corporate Drive, Birmingham, AL 35242, is the Intermediary for this offering and is not an affiliate of or connected with the Issuer. Please check our background on FINRA's BrokerCheck.

DealMaker Securities LLC does not make investment recommendations.

DealMaker Securities LLC is NOT placing or selling these securities on behalf of the Issuer.

DealMaker Securities LLC is NOT soliciting this investment or making any recommendations by collecting, reviewing, and processing an Investor's documentation for this investment.

DealMaker Securities LLC conducts Anti-Money Laundering, Identity and Bad Actor Disqualification reviews of the Issuer, and confirms they are a registered business in good standing.

DealMaker Securities LLC is NOT vetting or approving the information provided by the Issuer or the Issuer itself.

Contact information is provided for Investors to make inquiries and requests to DealMaker Securities LLC regarding Regulation CF in general, or the status of such investor's submitted documentation, specifically. DealMaker Securities LLC may direct Investors to specific sections of the Offering Circular to locate information or answers to their inquiry but does not opine or provide guidance on issuer related matters.